Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for warfarin
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on warfarin or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on warfarin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. 8413432 1993 11 09 1993 11 09 2013 11 21 0028-4793 329 19 1993 Nov 04 The New England journal of medicine N. Engl. J. Med. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. 1370-6 Deep-vein thrombosis is a potentially life-threatening (...) complication of total hip or knee replacement. There are few data on the effectiveness and safety of warfarin as compared with low-molecular-weight heparin as prophylaxis against this problem. We therefore performed a randomized, double-blind trial in 1436 patients to evaluate the effectiveness and safety of low-molecular-weight heparin (given subcutaneously once daily) as compared with adjusted-dose warfarin to prevent venous thrombosis after hip or knee replacement. Treatment with the drugs was started
Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. 1406859 1992 11 23 1992 11 23 2013 11 21 0028-4793 327 20 1992 Nov 12 The New England journal of medicine N. Engl. J. Med. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. 1406-12 Nonrheumatic (...) atrial fibrillation is common among the elderly and is associated with an increased risk of stroke. We investigated whether anticoagulation with warfarin would reduce this risk. We conducted a randomized, double-blind, placebo-controlled study to evaluate low-intensity anticoagulation with warfarin (prothrombin-time ratio, 1.2 to 1.5) in 571 men with chronic nonrheumatic atrial fibrillation; 525 patients had not previously had a cerebral infarction, whereas 46 patients had previously had such an event
Comparison of warfarin and external pneumatic compression in prevention of venous thrombosis after total hip replacement. 1583760 1992 06 16 1992 06 16 2016 10 17 0098-7484 267 21 1992 Jun 03 JAMA JAMA Comparison of warfarin and external pneumatic compression in prevention of venous thrombosis after total hip replacement. 2911-5 To compare the effectiveness and safety of warfarin and external pneumatic compression (EPC) in prevention of venous thrombosis after total hip replacement. Prospective (...) warfarin in a low-intensity regimen beginning 10 to 14 days preoperatively. Prophylaxis was continued until venography. Venous thrombosis was diagnosed by venography between postoperative days 6 and 8. Bleeding was assessed by surgical blood loss, transfusion requirements, changes in hematocrit, and clinically identified bleeding complications. The total incidence of venous thrombosis was virtually the same in the warfarin and EPC groups (31% vs 27%), but the distribution of thrombi was different
Efficacy of fixed minidose warfarin prophylaxis in total hip replacement. 1884058 1991 10 04 1991 10 04 2016 11 23 0959-8138 303 6796 1991 Jul 27 BMJ (Clinical research ed.) BMJ Efficacy of fixed minidose warfarin prophylaxis in total hip replacement. 219-20 To determine whether a small fixed perioperative dose of warfarin would prevent deep vein thrombosis after total hip replacement. Prospective, randomised, double blind placebo controlled trial. Winford Orthopaedic Hospital, Bristol. 148 (...) patients having primary total hip replacement. Warfarin 1 mg given daily for one week before and three weeks after surgery. Deep vein thrombosis diagnosed by the iodine-125 labelled fibrinogen uptake method. Deep vein thrombosis occurred in 25 (34%) of the patients given warfarin and 19 (26%) of the controls (difference 8%; 95% confidence interval -6.8% to 22.8%). Fixed minidose warfarin does not prevent deep vein thrombosis after total hip replacement. Fordyce M J MJ Winford Orthopaedic Hospital
The effect of warfarin on mortality and reinfarction after myocardial infarction. 2194126 1990 08 06 1990 08 06 2013 11 21 0028-4793 323 3 1990 Jul 19 The New England journal of medicine N. Engl. J. Med. The effect of warfarin on mortality and reinfarction after myocardial infarction. 147-52 The use of oral anticoagulation in the long-term treatment of survivors of acute myocardial infarction has been highly controversial. We therefore randomly assigned 1214 patients who had recovered from (...) acute myocardial infarction (mean interval from the onset of symptoms to randomization, 27 days) to treatment with warfarin (607 patients) or placebo (607 patients) for an average of 37 months (range, 24 to 63). At the end of the treatment period, there had been 123 deaths in the placebo group and 94 in the warfarin group--a reduction in risk of 24 percent (95 percent confidence interval, 4 to 44 percent; P = 0.027). A total of 124 patients in the placebo group had reinfarctions, as compared with 82
The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. 2233931 1990 12 11 1990 12 11 2013 11 21 0028-4793 323 22 1990 Nov 29 The New England journal of medicine N. Engl. J. Med. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. 1505-11 (...) Nonrheumatic atrial fibrillation increases the risk of stroke, presumably from atrial thromboemboli. There is uncertainty about the efficacy and risks of long-term warfarin therapy to prevent stroke. We conducted an unblinded, randomized, controlled trial of long-term, low-dose warfarin therapy (target prothrombin-time ratio, 1.2 to 1.5) in patients with nonrheumatic atrial fibrillation. The control group was not given warfarin but could choose to take aspirin. A total of 420 patients entered the trial
Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin. 2495079 1989 05 15 1989 05 15 2013 11 21 0959-8138 298 6672 1989 Feb 25 BMJ (Clinical research ed.) BMJ Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin. 493-6 To investigate the suitability of treatment with low dose aspirin or warfarin, or both, as possible prophylaxis against cardiovascular disease by determining the effect on gastric mucosal bleeding. Randomised crossover trial (...) . Academic department of therapeutics. Twenty healthy male volunteers aged 19-22. On separate occasions and in randomised order all subjects received aspirin 75 mg, warfarin, or aspirin 75 mg combined with warfarin. Each treatment was given for 12 days or (when warfarin was used) for longer if necessary until the international normalised ratio of the prothrombin time was stable at 1.4-1.6. Loss of blood over 10 minutes into gastric washings. Bleeding over 10 minutes into gastric washings under baseline
Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. 2563096 1989 02 23 1989 02 23 2015 06 16 0140-6736 1 8631 1989 Jan 28 Lancet (London, England) Lancet Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. 175-9 From November, 1985, to June, 1988, 1007 outpatients (...) with chronic non-rheumatic atrial fibrillation (AF) entered a randomised trial; 335 received anticoagulation with warfarin openly, and in a double-blind study 336 received aspirin 75 mg once daily and 336 placebo. Each patient was followed up for 2 years or until termination of the trial. The primary endpoint was a thromboembolic complication (stroke, transient cerebral ischaemic attack, or embolic complications to the viscera and extremities). The secondary endpoint was death. The incidence
Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. 2878173 1987 01 06 1987 01 06 2015 06 16 0140-6736 2 8519 1986 Dec 06 Lancet (London, England) Lancet Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. 1293-6 Two anticoagulant regimens, similar except for the timing of warfarin therapy, were compared in patients with clinically submassive venous thromboembolism (VTE). Warfarin was begun (...) femoral veins) 3.6% of group S but no group L patients had symptomless proximal extension. The incidence of bleeding was similar with both regimens. Outpatient follow-up showed no excess recurrent VTE in either treatment group. Early warfarin treatment significantly shortened hospital stay by an average of 3.9 days (30%) in patients admitted solely because of VTE. Gallus A A Jackaman J J Tillett J J Mills W W Wycherley A A eng Clinical Trial Comparative Study Journal Article Randomized Controlled
Two-step warfarin therapy. Prevention of postoperative venous thrombosis without excessive bleeding. 6184493 1983 02 25 1983 02 25 2016 11 23 0098-7484 249 3 1983 Jan 21 JAMA JAMA Two-step warfarin therapy. Prevention of postoperative venous thrombosis without excessive bleeding. 374-8 In a randomized, prospective trial of 100 patients, we have studied the safety and efficacy of warfarin sodium in comparison with that of dextran 40 in the prevention of venous thrombosis in patients at high risk (...) for deep vein thrombosis after elective total hip or knee replacement. Warfarin was given in a new two-step regimen designed to avoid bleeding complications while still preventing venous thrombosis. A low dose of warfarin was started ten to 14 days preoperatively, and the prothrombin time was regulated to between 1.5 and 3 seconds longer than control at the time of surgery; immediately after surgery, the dose was increased to prolong the prothrombin time to 1.5 times control. The overall incidence of venous thrombosis
Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. 7033782 1982 03 13 1982 03 13 2013 11 21 0028-4793 306 4 1982 Jan 28 The New England journal of medicine N. Engl. J. Med. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. 189-94 Previously, we compared fixed low doses of heparin with adjusted doses of warfarin for the long-term treatment of venous thrombosis; in that study low-dose heparin (...) was ineffective in preventing recurrence in patients with proximal-vein thrombosis. We have now completed a randomized trial comparing adjusted doses of heparin and of warfarin for prevention of recurrent venous thromboembolism in patients with proximal-vein thrombosis. One hundred six consecutive patients with acute proximal-vein thrombosis confirmed by venography were treated with intravenous heparin and then randomized to secondary prophylaxis. Two of 53 patients receiving heparin, as compared with one
Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study No. 75. 6257941 1981 04 21 1981 04 21 2016 10 17 0098-7484 245 8 1981 Feb 27 JAMA JAMA Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study No. 75. 831-5 In a controlled, randomized study, survival of patients with small cell carcinoma of the lung (SCCL) was prolonged on addition of warfarin sodium to combination chemotherapy plus radiation (...) therapy. Median survival for 25 control patients was 24 weeks and for 25 warfarin-treated patients was 50 weeks. This difference could not be accounted for by differences between groups in performance status, extent of disease, age, or sex. The survival advantage associated with warfarin administration was observed both for patients with extensive disease and for those who failed to achieve complete or partial remission. The warfarin-treated group also demonstrated a significantly increased time to first
Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. 384248 1979 11 28 1979 11 28 2013 11 21 0028-4793 301 16 1979 Oct 18 The New England journal of medicine N. Engl. J. Med. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. 855-8 Acute deep-vein thrombosis is usually treated with intravenous heparin for a number of days, then with oral anticoagulants for weeks to months. We have compared adjusted-dose warfarin sodium (...) with fixed low-dose subcutaneous heparin in the prevention of recurrent deep-vein thrombosis. Sixty-eight patients with acute deep-vein thrombosis confirmed by venography were treated with intravenous heparin and then randomized to secondary prophylaxis. Nine of 35 patients receiving subcutaneous heparin, but none of 33 receiving warfarin sodium, had new episodes of objectively documented venous thromboembolism (P = 0.001). Seven patients on warfarin sodium experienced bleeding complications (of which
Warfarin sodium in prevention of deep venous thrombosis and pulmonary embolism in patients with fractured neck of femur. 62111 1976 12 30 1976 12 30 2015 06 16 0140-6736 2 7991 1976 Oct 23 Lancet (London, England) Lancet Warfarin sodium in prevention of deep venous thrombosis and pulmonary embolism in patients with fractured neck of femur. 869-72 In a prospective controlled randomised trial, the prophylactic value of warfarin sodium (in doses aimed at maintaining a "Thrombotest" value of 10 (...) and control groups was not significant, indicating that causes of death other than pulmonary embolism are of major importance in these elderly patients. A case is made out for prophylactic anticoagulation on a selective basis. Morris G K GK Mitchell J R JR eng Clinical Trial Journal Article Randomized Controlled Trial England Lancet 2985213R 0140-6736 5Q7ZVV76EI Warfarin AIM IM Aged Clinical Trials as Topic Drug Evaluation Female Femoral Neck Fractures complications surgery Follow-Up Studies Hemorrhage